Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, Wegovy can affect your menstrual cycle. Semaglutide causes significant weight loss, and weight loss itself is one of the most well-established drivers of hormonal shifts that alter cycle length, flow, or regularity. For some women, periods become more predictable as weight decreases; for others, irregular bleeding or missed cycles appear during the early months of treatment. This is a prescription-only medicine — a clinician reviews your full picture before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks is some version of: "My period has changed since starting Wegovy, should I be worried?" The short answer is that most cycle changes during semaglutide treatment trace back to the weight loss itself rather than any direct hormonal action of the drug. Fat tissue produces oestrogen; as body weight falls, oestrogen output shifts, and the hypothalamic-pituitary axis (the hormonal chain that governs ovulation) recalibrates. That recalibration can show up as lighter periods, heavier periods, earlier or later cycles, or a skipped month.
The NHS medicines guidance on semaglutide does not list menstrual disruption as a formal side effect of the drug, which reflects the evidence base: no large trial has identified a direct pharmacological mechanism by which semaglutide alters the menstrual cycle independently of weight change. That said, the weight changes semaglutide produces can be rapid and substantial, and rapid weight loss is a recognised trigger for cycle irregularity in otherwise healthy women.
So the decision you're weighing is not really "Wegovy or no Wegovy", it's understanding which changes are expected, which are a reason to pause and speak to your GP, and what practical steps (especially around contraception) need to be in place from day one. The sections below cover each of those factors.
When body-fat percentage falls meaningfully, several hormonal changes happen in parallel. Insulin resistance drops, which lowers circulating insulin and, in turn, reduces ovarian androgen production. For women with polycystic ovary syndrome (PCOS), this is often transformative: elevated androgens and insulin are the core drivers of anovulatory cycles, and reducing them can restore ovulation for the first time in years. Many women with PCOS find their periods become more regular as they lose weight on semaglutide, a welcome effect, but also one that can catch people off guard if they had assumed they couldn't conceive.
For women without PCOS, the hormonal trajectory is less linear. Moderate weight loss tends to have little effect on cycle regularity. Faster or greater losses (the kind seen in clinical trials of Wegovy, where average reductions reached around 15% of body weight over 68 weeks per data published in STEP 1 in the New England Journal of Medicine) can briefly suppress ovulation or shift cycle timing as the body adjusts. This generally settles once weight stabilises. Persistent amenorrhoea (no period for three or more months) that isn't explained by pregnancy warrants a GP review regardless of treatment.
It is worth knowing that fertility can return or increase during treatment, sometimes before a regular cycle resumes. A missed period on Wegovy is not automatically a sign of suppressed ovulation; it can mean the opposite. A pregnancy test is the sensible first step.
Semaglutide slows how quickly your stomach empties its contents into the small intestine. For most medicines this makes little practical difference. For oral contraceptive pills, which depend on timely intestinal absorption, there is a theoretical risk that delayed gastric emptying could reduce absorption, and with it, contraceptive efficacy. The NHS guidance on weight management injections advises women on oral contraceptives to discuss this with their prescriber and consider adding a barrier method, particularly in the early weeks of treatment.
This is distinct from the tirzepatide guidance, which specifies a formal four-week window for back-up contraception at treatment start and after each dose increase. For semaglutide the evidence is less prescriptive, but the precautionary advice stands: if pregnancy is not planned, talk to your prescriber before starting. If you're exploring whether Wegovy is the right treatment for you, starting a consultation is the place to put those questions directly to a clinical team.
Transdermal contraception (patches, implants, hormonal coils) bypasses the absorption question entirely and is often the cleanest option during weight-loss treatment. Your GP or prescriber can advise on switching.
Most menstrual changes in the first two to three months of Wegovy treatment are self-limiting and don't require stopping. Expect some irregularity while your body adjusts. Keep a brief cycle log if changes concern you, patterns are easier to assess than recalled impressions.
Seek GP advice if: periods stop entirely for three months or more (and you've ruled out pregnancy); bleeding becomes unusually heavy or prolonged; you experience pelvic pain that's new or worsening; or if a pregnancy test is positive. Wegovy is not recommended during pregnancy, and you should stop treatment and contact your clinical team straight away if that test comes back positive.
On the contraception question, don't wait, sort it before your first pen arrives. And if you haven't yet started treatment and want to understand the full picture, including how Wegovy fits your specific health history, you can check your eligibility with our prescribers. Every consultation at nume is reviewed by a GPhC-registered Independent Prescriber on the same day, a real clinician, reading your answers, not software processing them. There are no subscriptions and no hidden fees; if treatment isn't clinically suitable, you'll hear that plainly too.
For a broader look at how this treatment works and what the evidence says, the Wegovy overview covers the full picture. Our semaglutide page goes deeper on the mechanism. And if you want to explore how periods and weight-loss treatment interact across different scenarios, more detail on Wegovy's effect on periods is available too, with a dedicated guide to how Wegovy can affect your period covering the full range of changes people experience. If you are based in Northumberland and considering treatment locally, our semaglutide service in Amble is also available through the same prescribing process.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.